A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.

@article{Mole2001APT,
  title={A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.},
  author={Larry Mole and D Schmidgall and Mark Holodniy},
  journal={Journal of acquired immune deficiency syndromes},
  year={2001},
  volume={27 3},
  pages={260-5}
}
OBJECTIVE To evaluate the tolerance, pharmacokinetics, and virologic and immunologic outcomes of once-daily indinavir, ritonavir, didanosine, and lamivudine in HIV-seropositive individuals. DESIGN Open-label 24-week pilot study. PATIENTS Ten HIV-seropositive subjects who were either antiretroviral-naive or minimally experienced with short-term single-or dual-nucleoside therapy provided informed consent and were enrolled. All subjects received didanosine (400 mg) 30 to 60 minutes before a… CONTINUE READING